Because GlaxoSmithKline wants to double its China and India revenues by 2015, the company will significantly reduce its prices – as much as 70% – to raise revenues. “There’s absolutely a land grab [in emerging markets] going on right now because obviously there’s no growth in the US and Europe, or very little growth,” said Abbas Hussain, President of Emerging Markets for Glaxo. “There’s a real fight on for market share.” More details...

Stock Symbol: (NYSE: GSK)